SCHEMBL5113034

SCHEMBL5113034

CCOC(=O)C(C)(Cc1ccc(O)cc1)Oc1ccc(C(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 1/20 0.52
ESRRG P62508 4/20 0.45
NR4A2 P43354 1/20 0.45
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
EPHX2 P34913 2/20 0.44
NR1H4 Q96RI1 2/20 0.44
ESRRB O95718 1/20 0.44
PPARA Q07869 5/20 0.44
ABCB11 O95342 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
HTR2A P28223 1/20 0.44
PMP22 Q01453 1/20 0.44
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ESR1 P03372 4/20 0.42
ESR2 Q92731 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116683 0.90 OPRK1 (0.50) OPRK1EPHX2PPARAABCB11CYP1A2
SCHEMBL5118352 0.90 OPRK1 (0.50) OPRK1EPHX2PPARAABCB11CYP1A2
SCHEMBL5110571 0.90 OPRK1 (0.54) OPRK1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5110581 0.90 OPRK1 (0.54) OPRK1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5123296 0.88 OPRK1 (0.53) OPRK1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5109513 0.88 OPRK1 (0.53) OPRK1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5117353 0.87 OPRK1 (0.52) OPRK1NR4A2PPARAABCB11CYP1A2
SCHEMBL5112583 0.87 OPRK1 (0.69) OPRK1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5124378 0.87 OPRK1 (0.52) OPRK1EPHX2NR1H4PPARAABCB11
SCHEMBL5113038 0.87 OPRK1 (0.52) OPRK1NR4A2PPARAABCB11CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345070-B2 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ELI LILLY AND COMPANY (US) 2008-03-18 US disclosed
US-7345070-B2 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ELI LILLY AND COMPANY (US) 2008-03-18 US disclosed
US-7345070-B2 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid ELI LILLY AND COMPANY (US) 2008-03-18 US disclosed
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 EP disclosed
EP-1313716-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-05-02 EP disclosed
EP-1313716-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-05-02 EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 US disclosed
US-20050245584-A1 Peroxisome proliferator activated receptor agonists BROOKS DAWN A 2005-11-03 US disclosed
US-6930120-B2 Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY (US) 2005-08-16 US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
US-20040097590-A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists BROOKS DAWN ALISA (US) 2004-05-20 US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
EP-1313716-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed
WO-2002016331-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG OPRK1 497/4885ESRRG 252/4885NR4A2 30/4885
US-20040097590-A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists PPARA, PPARG, PPARD OPRK1 399/4885ESRRG 364/4885NR4A2 33/4885
US-20050245584-A1 Peroxisome proliferator activated receptor agonists PPARG, PPARA, PPARD OPRK1 642/4885ESRRG 249/4885NR4A2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.